Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04862286
PHASE3

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

Sponsor: AbbVie

View on ClinicalTrials.gov

Summary

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study M19-977. Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide. Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Official title: OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1)

Key Details

Gender

All

Age Range

6 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

132

Start Date

2021-07-24

Completion Date

2028-04

Last Updated

2025-08-12

Healthy Volunteers

No

Conditions

Interventions

DRUG

Risankizumab

Subcutaneous (SC) injection.

Locations (41)

UAB Department of Dermatology /ID# 252305

Birmingham, Alabama, United States

First OC Dermatology /ID# 226942

Fountain Valley, California, United States

Integrative Skin Science and Research /ID# 226108

Sacramento, California, United States

University of California San Diego - Rady Children's Hospital San Diego /ID# 252348

San Diego, California, United States

Solutions Through Adv Rch /ID# 226104

Jacksonville, Florida, United States

Olympian Clinical Research- St. Petersburg /ID# 226106

St. Petersburg, Florida, United States

Advanced Clinical Research Institute /ID# 248827

Tampa, Florida, United States

University Dermatology and Vein Clinic, LLC /ID# 226100

Darien, Illinois, United States

Arlington Dermatology /ID# 226097

Rolling Meadows, Illinois, United States

Skin Cancer and Dermatology Institute - Reno /ID# 248828

Reno, Nevada, United States

Univ Hosp Cleveland /ID# 248825

Cleveland, Ohio, United States

Apex Clinical Research Center /ID# 248830

Mayfield Heights, Ohio, United States

Medical University of South Carolina /ID# 248831

Charleston, South Carolina, United States

West Virginia University Hospitals /ID# 263438

Morgantown, West Virginia, United States

Wisconsin Medical Center /ID# 263437

Milwaukee, Wisconsin, United States

Karma Clinical Trials /ID# 233985

St. John's, Newfoundland and Labrador, Canada

Hospital for Sick Children /ID# 233986

Toronto, Ontario, Canada

Fachklinik Bad Bentheim /ID# 243904

Bad Bentheim, Lower Saxony, Germany

Universitaetsklinikum Bonn /ID# 243910

Bonn, North Rhine-Westphalia, Germany

Universitaetsklinikum Muenster /ID# 243905

Münster, North Rhine-Westphalia, Germany

Universitaetsmedizin Mainz /ID# 243907

Mainz, Rhineland-Palatinate, Germany

Universitaetsklinikum Carl Gustav Carus Dresden /ID# 243908

Dresden, Saxony, Germany

Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 243883

Kiel, Schleswig-Holstein, Germany

Nagoya City University Hospital /ID# 248429

Nagoya, Aichi-ken, Japan

Mie University Hospital /ID# 263008

Tsu, Mie-ken, Japan

Kansai Medical University Hirakata Hospital /ID# 252332

Hirakata-shi, Osaka, Japan

Tokyo Medical University Hospital /ID# 252331

Shinjuku-ku, Tokyo, Japan

High-Med Przychodnia Specjalistyczna /ID# 243846

Warsaw, Masovian Voivodeship, Poland

Uniwersytecki Szpital Kliniczny im. F. Chopina w Rzeszowie /ID# 243850

Rzeszów, Podkarpackie Voivodeship, Poland

Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 243849

Gdansk, Pomeranian Voivodeship, Poland

Dermed Centrum Medyczne Sp. z o.o /ID# 243847

Lodz, Łódź Voivodeship, Poland

Dermoklinika Medical Center /ID# 243848

Lodz, Łódź Voivodeship, Poland

Hospital Sant Joan de Deu /ID# 241103

Esplugues de Llobregat, Barcelona, Spain

Hospital General Universitario Gregorio Maranon /ID# 241099

Madrid, Spain

Hospital Universitario Infanta Leonor /ID# 241100

Madrid, Spain

Hospital Universitario 12 de Octubre /ID# 241102

Madrid, Spain

Complejo Hospitalario Universitario de Pontevedra /ID# 241101

Pontevedra, Spain

Royal Devon & Exeter Hospital /ID# 245101

Exeter, Devon, United Kingdom

Derriford Hospital and the Royal Eye Infirmary /ID# 245104

Plymouth, Devon, United Kingdom

Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 245100

London, Greater London, United Kingdom

Chelsea and Westminster Hospital /ID# 245102

London, Greater London, United Kingdom